{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:40:41Z","timestamp":1768520441864,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD030311"],"award-info":[{"award-number":["S10OD030311"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CPRIT-RP220662"],"award-info":[{"award-number":["CPRIT-RP220662"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1I01BX000280"],"award-info":[{"award-number":["1I01BX000280"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK6BX004207"],"award-info":[{"award-number":["IK6BX004207"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023736","name":"Office of the Vice President for Research and Partnerships","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA054174"],"award-info":[{"award-number":["P30 CA054174"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bbagen.2025.130828","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T19:15:19Z","timestamp":1748459719000},"page":"130828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ferroptosis induction, androgen biosynthesis disruption and prostate cancer suppression by androgen and vitamin D combination"],"prefix":"10.1016","volume":"1869","author":[{"given":"Bobae","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subash","family":"Khadka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungmi","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Vaquiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okunola","family":"Igbekoyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung S.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bandana","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbagen.2025.130828_bb0005","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbagen.2025.130828_bb0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagen.2025.130828_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40487-020-00119-z","article-title":"Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first line setting","volume":"8","author":"Ng","year":"2020","journal-title":"Oncol. Ther."},{"issue":"892","key":"10.1016\/j.bbagen.2025.130828_bb0020","article-title":"Precision targets for intercepting lethal progression of prostate cancer: potential avenues for personalized therapy","volume":"14","author":"Christenson","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.bbagen.2025.130828_bb0025","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bbagen.2025.130828_bb0030","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1210\/en.2019-00366","article-title":"HSD3B1 genotypes conferring adrenal-restrictive and adrenal-permissivephenotypes in prostate cancer and beyond","volume":"160","author":"Sabharwal","year":"2019","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.bbagen.2025.130828_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.6496","article-title":"HSD3B1Genotype and clinical outcomes in metastatic castration-sensitive prostate cancer","volume":"6","author":"Hearn","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbagen.2025.130828_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","article-title":"AKR1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase): roles in malignancy and endocrine disorders","volume":"489","author":"Penning","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.bbagen.2025.130828_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/endocr\/bqz042","article-title":"Inhibitory interplay of SULT2B1b sulfotransferase with AKR1C3 Aldo-keto reductase in prostate cancer","volume":"161","author":"Park","year":"2020","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.bbagen.2025.130828_bb0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/er.2018-00089","article-title":"Structural and functional biology of Aldo-Keto reductase steroid-transforming enzymes","volume":"40","author":"Penning","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbagen.2025.130828_bb0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.steroids.2014.01.013","article-title":"5\u03b2-reduced steroids and human \u03944\u20133-ketosteroid 5\u03b2-reductase (AKR1D1)","volume":"83","author":"Chen","year":"2014","journal-title":"Steroids"},{"issue":"3","key":"10.1016\/j.bbagen.2025.130828_bb0060","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/0008-5472.CAN-06-1593","article-title":"Impaired dihydrotestosteronecatabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling","volume":"67","author":"Ji","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagen.2025.130828_bb0065","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3691","article-title":"The role of vitamin D inreducing cancer risk and progression","volume":"14","author":"Feldman","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbagen.2025.130828_bb0070","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1301\/nr.2007.aug.S116-S117","article-title":"Interactions between vitamin D and androgen receptor signaling in prostate cancer cells","volume":"65","author":"Weigel","year":"2007","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.bbagen.2025.130828_bb0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1158\/1940-6207.CAPR-18-0401","article-title":"VitaminD signaling suppresses early prostate carcinogenesis in TGAPT121MICE","volume":"12","author":"Fleet","year":"2019","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.bbagen.2025.130828_bb0080","doi-asserted-by":"crossref","unstructured":"Ahn J, Park S, Zuniga B, Bera A, Song CS,Chatterjee B, Vitamin D in prostate cancer, in:Vitamins and Hormones(Litwack G ed), Elsevier\/Academic press, Vol. 100: pp. 321\u2013356, 2016.doi: https:\/\/doi.org\/10.1016\/bs.vh.2015.10.012; PMID: 26827958.","DOI":"10.1016\/bs.vh.2015.10.012"},{"issue":"6","key":"10.1016\/j.bbagen.2025.130828_bb0085","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/17512433.1.6.803","article-title":"Vitamin D, vitamin D analogs (deltanoids) and prostate cancer","volume":"1","author":"Brown","year":"2008","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.bbagen.2025.130828_bb0090","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1634\/theoncologist.2012-0051","article-title":"Calcium and vitamin D supplementation during AndrogenDeprivation therapy for prostate cancer: a critical review","volume":"17","author":"Datta","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.bbagen.2025.130828_bb0095","doi-asserted-by":"crossref","first-page":"62240","DOI":"10.18632\/oncotarget.11404","article-title":"Dual targetingof androgen receptor and mTORC1 by salinomycin in prostate cancer","volume":"7","author":"Mirkheshti","year":"2016","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.bbagen.2025.130828_bb0100","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1101\/gad.8.13.1514","article-title":"Autoregulatory control of E2F1 expression in responseto positive and negative regulators of cell cycle progression","volume":"8","author":"Johnson","year":"1994","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.bbagen.2025.130828_bb0105","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/oby.2006.75","article-title":"Dihydrotestosterone treatment results in obesity and altered lipid metabolism in Orchi-dectomized mice","volume":"14","author":"Move\u2019rare-Skrtic","year":"2006","journal-title":"Obesity"},{"issue":"58","key":"10.1016\/j.bbagen.2025.130828_bb0110","article-title":"Effects of 1a,25dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells","volume":"10","author":"Wang","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbagen.2025.130828_bb0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-59745-157-4_4","article-title":"LC3 and autophagy","volume":"445","author":"Tanida","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbagen.2025.130828_bb0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev-cancerbio-030518-055844","article-title":"The hallmarks of ferroptosis","volume":"3","author":"Dixon","year":"2019","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.bbagen.2025.130828_bb0125","article-title":"Ferritinophagy, a form of autophagicferroptosis: New insights into cancer treatment","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Pharmcol."},{"key":"10.1016\/j.bbagen.2025.130828_bb0130","doi-asserted-by":"crossref","first-page":"100046","DOI":"10.1074\/jbc.RA120.014479","article-title":"The 89-kDa PARP1cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis","volume":"296","author":"Mashimo","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2025.130828_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi2011","article-title":"The road to death: caspases, cleavage, and pores","volume":"9","author":"Dixit","year":"2023","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.bbagen.2025.130828_bb0140","article-title":"Necroptosis: MLKL polymerization","volume":"4","author":"Johnston","year":"2018","journal-title":"J. Nat. Sci."},{"key":"10.1016\/j.bbagen.2025.130828_bb0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/iub.1616","article-title":"Iron and ferroptosis: a still ill-defined liaison","volume":"69","author":"Doll","year":"2017","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bbagen.2025.130828_bb0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13148","article-title":"Quantitative proteomicsidentifies NCOA4 as the cargo receptor mediating ferritinophagy","volume":"509","author":"Mancias","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbagen.2025.130828_bb0155","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/ncb3053","article-title":"Selective VPS34 inhibitorblocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasisin vivo","volume":"16","author":"Dowdle","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbagen.2025.130828_bb0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","article-title":"Ferroptosis: molecular mechanisms and healthimplications","volume":"31","author":"Tang","year":"2021","journal-title":"Cell Res."},{"issue":"21","key":"10.1016\/j.bbagen.2025.130828_bb0165","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1073\/pnas.93.21.11802","article-title":"Human prostate tumor growth in athymic mice:inhibitionby androgen and stimulation by finasteride","volume":"93","author":"Umekita","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"18","key":"10.1016\/j.bbagen.2025.130828_bb0170","doi-asserted-by":"crossref","first-page":"10185","DOI":"10.1073\/pnas.97.18.10185","article-title":"Androgen-induced proliferativequiescence in prostate cancer cells: the role of AS3 as its mediator","volume":"97","author":"Geck","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbagen.2025.130828_bb0175","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1158\/0008-5472.CAN-20-3607","article-title":"Supraphysiologic testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate Cancer","volume":"81","author":"Kumar","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagen.2025.130828_bb0180","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pros.24328","article-title":"Bipolar androgen therapy (BAT): a patient\u2019sguide","volume":"82","author":"Denmeade","year":"2022","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.bbagen.2025.130828_bb0185","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3389\/fimmu.2020.01647","article-title":"Supraphysiological levels of testosterone induce vascular dysfunction via activation of the NLRP3 inflammasome","volume":"31","author":"Alves","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbagen.2025.130828_bb0190","first-page":"1275","article-title":"Silencing of thetranscriptional factor ZEB1 alters the steroidogenic pathway, and increases the concentrationof testosterone and DHT in DU145 cells","volume":"41","author":"Herrera","year":"2019","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.bbagen.2025.130828_bb0195","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41585-022-00686-y","article-title":"The testosterone paradox of advancedprostate cancer: mechanistic insights and clinical implications","volume":"20","author":"Kumar","year":"2023","journal-title":"Nat. Rev. Urol."},{"issue":"10","key":"10.1016\/j.bbagen.2025.130828_bb0200","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1172\/JCI127613","article-title":"Supraphysiological androgens suppress prostate cancer growth through androgen receptor\u2013 mediated DNA damage","volume":"129","author":"Chatterjee","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bbagen.2025.130828_bb0205","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clgc.2021.08.001","article-title":"Antonarakis ES, Molecular and clinical characterization of patients with metastatic castration resistant prostate cancer achieving deep responses to bipolar androgen therapy","volume":"20","author":"Markowski","year":"2022","journal-title":"Clin. Genitourin. Cancer"}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030441652500073X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030441652500073X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:06:28Z","timestamp":1762290388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030441652500073X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S030441652500073X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2025.130828","relation":{},"ISSN":["0304-4165"],"issn-type":[{"value":"0304-4165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ferroptosis induction, androgen biosynthesis disruption and prostate cancer suppression by androgen and vitamin D combination","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2025.130828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130828"}}